生物制药学

刘丹

姓名:刘丹

职称:教授

邮箱:Liudan1201jx@ncu.edu.cn

籍贯:辽宁

导师类型:博士生导师

主讲课程:药理学

个人主页:

研究方向

中药药理;抗炎与免疫药理;肿瘤药理

教育经历

1996.9~2001.7:江西医学院,临床医学专业,医学学士

2003.9~2006.7:南昌大学药学院,医学硕士

2006.9~2009.7:南昌大学,外科学专业,外科学博士

2009.10~2012. 10:江西省人民医院, 博士后

2014.5~2015.5:美国波士顿大学,访问交流

工作履历

2001.7~至今:南昌大学药学院

学术兼职

 中国药理学会会员

 中国药理学会教学与科普专业委员会委员

 中国药理学会来华留学生教学专业委员会常务委员

主要业绩

主持国家自然科学基金课题5项,主持省自然科学3项,中医药管理局重点项目1项。在国内外权威刊物发表学术论文60余篇,其中SCI收录论文40余篇。参编人民卫生出版及高等教育出版社书著3本。

1.主持的国家自然科学基金项目/课题

(1)国家自然科学基金地区项目(82560807),“小柴胡汤改善脓毒症急性肝损伤机制研究”,资助32万元,2026-2029年。

(2)国家自然科学基金地区项目(81760587),“Bcl-2/VDAC1介导的线粒体凋亡途径在牛磺酸抗铁过载所致肝损伤中的作用”,资助35万元,2018-2021年。


(3)国家自然科学基金地区项目(81460551),“14-3-3?/GSK3/?-catenin通路在内毒素耐受交叉保护心肌缺血/再灌注损伤中的作用”,资助55万元,2015-2018年。

(4)国家自然科学基金青年科学基金项目(81100104),“AMPK?2亚细胞定位在氯离子介导心肌缺血再灌注损伤中的机制研究”,资助20万元,2012-2014年。

(5)国家自然科学基金地区项目(30860271),“心肌缺血再灌注损伤中ROS爆发性形成及其作用靶点与氯离子动态变化关系的研究”,资助25万元,2009-2011年。


2.近五年代表性论文

(1)Shang Z, Zhou L, Liu Y, Yang X, Yao D, Zhai F, Liu B, Chen Y, Zhu X, Liu D, Yi B. Tongxie Yaofang attenuates ulcerative colitis by modulating gut microbiota and IL-10RA/NF-κB-mediated macrophage polarization. Phytomedicine. 2025; 148: 157459.

(2)Qiao Y, Lai S, Wang Y, Hu F, Liu Y, Zhai F, Zhang Z, Liu D, Huang H. Puerarin Attenuates Myocardial Ischemia-Reperfusion Damage by Targeting Ferroptosis through 14-3-3? Modulation. Am J Chin Med. 2025:1-20.

(3)Shujuan Zhang, BangHua Li, Xiaoqun Han, LinLin Ruan, Xingxing Fu, Yanglin Chen, Hongtao Wan, Xiaojian Zhu, Dan Liu, Bo Yi. Sanren Decoction Ameliorates Ulcerative Colitis by Modulating Gut Microbiota and Macrophage Polarization to Enhance Intestinal Barrier Function. Chin Med. 2025; 20(1): 128.

(4)Zhou L, Liu Y, Zhai F, Liu B, Liu D, Yi B. Mechanisms of corn silk polysaccharide in promoting colorectal Cancer progression: A multi-omics approach to microbiota, metabolomics, and transcriptomics. J Funct Foods. 2025;130:106937.

(5)Liu D, Lin S, Hu Y, Xiong J, Wan H, Chen Y, Ding T, Zhao H, Jiang R, Huang Z, Yao D, Li M, Zhu X, Yi B. HNRNPC stabilizes m6A-modified AC145207.5 to accelerate tumorigenesis in colorectal cancer by impeding the Nrf2/GPX4 axis-mediated ferroptosis. Noncoding RNA Res. 2025;13:43-56.

(6)Zhao H, Fu X, Wang Y, Shang Z, Li B, Zhou L, Liu Y, Liu D, Yi B. Therapeutic Potential of Vanillic Acid in Ulcerative Colitis Through Microbiota and Macrophage Modulation. Mol Nutr Food Res. 2025; 69(4):e202400785.

(7)Wang Y, Fu X, Shang Z, Qiao Y, Liu Y, Zhou L, Liu D. In vivo and in vitro study on the regulatory mechanism of XiaoChaiHu decoction on PANoptosis in sepsis-induced cardiomyopathy. J Ethnopharmacol. 2025; 336: 118740.

(8)Wang X, Liu R, Liu D. The Role of the MAPK Signaling Pathway in Cardiovascular Disease: Pathophysiological Mechanisms and Clinical Therapy. Int J Mol Sci. 2025; 26(6): 2667.

(9)Wang X, Lang F, Liu D. High-Salt Diet and Intestinal Microbiota: Influence on Cardiovascular Disease and Inflammatory Bowel Disease. Biology (Basel). 2024;13(9): 674.

(10)Jiang R, Ruan L, Ding T, Wan H, Chen Y, Zhu X, Huang Z, Yao D, Li M, Yi B, Liu D. Development of a prognostic gene signature and exploration of P4HA1 in the modulation of cuproptosis in colorectal cancer. Sci Rep. 2024;14(1): 31766.

(11)Ding T, Shang Z, Zhao H, Song R, Xiong J, He C, Liu D, Yi B. Anoikis-related gene signatures in colorectal cancer: implications for cell differentiation, immune infiltration, and prognostic prediction. Sci Rep. 2024;14(1):11525.

(12)Zhao H, Ding T, Chen Y, Yang W, Rao J, Liu D, Yi B. Arecoline aggravates acute ulcerative colitis in mice by affecting intestinal microbiota and serum metabolites. Front Immunol. 2023;14:1197922.

(13)Zhang X, Zeng Z, Liu Y, Liu D. Emerging Relevance of Ghrelin in Programmed Cell Death and Its Application in Diseases. Int J Mol Sci. 2023;24(24):17254.

(14)Wan H, Liu X, Chen Y, Tang R, Yi B, Liu D. Silencing of the ARK5 gene reverses the drug resistance of multidrug-resistant SGC7901/DDP gastric cancer cells. PeerJ. 2020; 8: e9560.

(15)Yao X, Jiao S, Qin M, Hu W, Yi B, Liu D. Vanillic Acid Alleviates Acute Myocardial Hypoxia/Reoxygenation Injury by Inhibiting Oxidative Stress. Oxid Med Cell Longev. 2020; 2020: 8348035.